{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:32:57Z","timestamp":1782408777459,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1124\/dmd.119.089391","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T22:45:18Z","timestamp":1579905918000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans"],"prefix":"10.1016","volume":"48","author":[{"given":"Ronald","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongwoo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Northcutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Babiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Almstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.089391_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1124\/dmd.119.089391_bib2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/jms.1033","article-title":"Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560","volume":"41","author":"Bateman","year":"2006","journal-title":"J Mass Spectrom"},{"key":"10.1124\/dmd.119.089391_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1124\/dmd.119.089391_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1124\/dmd.119.089391_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1124\/dmd.119.089391_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1124\/dmd.119.089391_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0168-9525(98)01658-8","article-title":"RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer","volume":"15","author":"Culbertson","year":"1999","journal-title":"Trends Genet"},{"key":"10.1124\/dmd.119.089391_bib8","doi-asserted-by":"crossref","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.119.089391_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1124\/dmd.119.089391_bib10","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2147\/NDT.S93873","article-title":"Current and emerging treatment strategies for Duchenne muscular dystrophy","volume":"12","author":"Mah","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1124\/dmd.119.089391_bib11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/dmd.119.089391_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0092-8674(01)00583-9","article-title":"When the message goes awry: disease-producing mutations that influence mRNA content and performance","volume":"107","author":"Mendell","year":"2001","journal-title":"Cell"},{"key":"10.1124\/dmd.119.089391_bib13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1124\/dmd.119.089391_bib14","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.119.089391_bib15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1124\/dmd.31.8.999","article-title":"Substituent effect on the reductive N-dearylation of 3-(indol-1-yl)-1,2-benzisoxazoles by rat liver microsomes","volume":"31","author":"Tschirret-Guth","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.089391_bib16","unstructured":"Viropharma Inc. (2002) Antiviral Drug Advisory Committee Briefing Document, Picovir (pleconaril), NDA: 21-245."},{"key":"10.1124\/dmd.119.089391_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1124\/dmd.119.089391_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0090-9556(25)08216-9","article-title":"Novel cleavage of the 1,2,4-oxadiazole ring in rat metabolism of SM-6586, a dihydropyridine calcium antagonist","volume":"21","author":"Yabuki","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.089391_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/dmd.107.018416","article-title":"Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs","volume":"36","author":"Zhang","year":"2008","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.089391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:53:32Z","timestamp":1740056012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0090955624080784"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.089391","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.089391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}